Dialysis Drug Reimbursement Should Be Based Solely On ASP, MedPAC Says
This article was originally published in The Pink Sheet Daily
Medicare Payment Advisory Committee unanimously recommends average sales price-based reimbursement for dialysis drugs in all settings. More timely updating of payment rates is cited as the main advantage of ASP-based reimbursement over reimbursement based on average acquisition payment.
You may also be interested in...
The Hospital Outpatient Prospective Payment System should include a payment adjustment for pharmaceutical handling costs, the Medicare Payment Advisory Committee recommended during an April 21 meeting in Washington, D.C
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter